Amphastar Pharmaceuticals (AMPH) Competitors $40.85 +0.01 (+0.02%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends AMPH vs. RVMD, LNTH, LEGN, NUVL, BPMC, ELAN, CYTK, TGTX, VKTX, and BBIOShould you be buying Amphastar Pharmaceuticals stock or one of its competitors? The main competitors of Amphastar Pharmaceuticals include Revolution Medicines (RVMD), Lantheus (LNTH), Legend Biotech (LEGN), Nuvalent (NUVL), Blueprint Medicines (BPMC), Elanco Animal Health (ELAN), Cytokinetics (CYTK), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry. Amphastar Pharmaceuticals vs. Revolution Medicines Lantheus Legend Biotech Nuvalent Blueprint Medicines Elanco Animal Health Cytokinetics TG Therapeutics Viking Therapeutics BridgeBio Pharma Amphastar Pharmaceuticals (NASDAQ:AMPH) and Revolution Medicines (NASDAQ:RVMD) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability. Does the media prefer AMPH or RVMD? In the previous week, Amphastar Pharmaceuticals and Amphastar Pharmaceuticals both had 9 articles in the media. Revolution Medicines' average media sentiment score of 1.27 beat Amphastar Pharmaceuticals' score of 0.99 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amphastar Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer AMPH or RVMD? Amphastar Pharmaceuticals presently has a consensus price target of $60.33, suggesting a potential upside of 47.69%. Revolution Medicines has a consensus price target of $63.67, suggesting a potential upside of 40.98%. Given Amphastar Pharmaceuticals' higher probable upside, research analysts plainly believe Amphastar Pharmaceuticals is more favorable than Revolution Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amphastar Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Revolution Medicines 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08 Which has preferable earnings & valuation, AMPH or RVMD? Amphastar Pharmaceuticals has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmphastar Pharmaceuticals$723.55M2.71$137.54M$3.0013.62Revolution Medicines$742K10,238.23-$436.37M-$3.59-12.58 Do insiders and institutionals have more ownership in AMPH or RVMD? 65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 27.1% of Amphastar Pharmaceuticals shares are held by insiders. Comparatively, 8.0% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is AMPH or RVMD more profitable? Amphastar Pharmaceuticals has a net margin of 21.80% compared to Revolution Medicines' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 26.44% beat Revolution Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Amphastar Pharmaceuticals21.80% 26.44% 11.89% Revolution Medicines N/A -33.67%-30.08% Which has more volatility & risk, AMPH or RVMD? Amphastar Pharmaceuticals has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500. Comparatively, Revolution Medicines has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Does the MarketBeat Community believe in AMPH or RVMD? Amphastar Pharmaceuticals received 302 more outperform votes than Revolution Medicines when rated by MarketBeat users. However, 75.63% of users gave Revolution Medicines an outperform vote while only 66.22% of users gave Amphastar Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAmphastar PharmaceuticalsOutperform Votes39266.22% Underperform Votes20033.78% Revolution MedicinesOutperform Votes9075.63% Underperform Votes2924.37% SummaryAmphastar Pharmaceuticals beats Revolution Medicines on 10 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaAI Crypto Tool Could Send One Coin SOARING…The #1 AI Coin to Buy Rapid growth predicted for little-known AI crypto projectDiscover our #1 crypto pick before it's too late. Get Amphastar Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMPH vs. The Competition Export to ExcelMetricAmphastar PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.96B$6.85B$5.17B$9.30BDividend YieldN/A3.06%4.77%4.06%P/E Ratio13.6210.58132.2217.52Price / Sales2.71285.171,256.58139.03Price / Cash9.9856.6540.7837.95Price / Book3.065.424.904.91Net Income$137.54M$151.28M$118.85M$225.61M7 Day Performance-6.39%-5.41%14.53%-1.46%1 Month Performance-8.43%0.41%17.44%5.38%1 Year Performance-27.83%16.10%35.31%22.72% Amphastar Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMPHAmphastar Pharmaceuticals4.8676 of 5 stars$40.85+0.0%$60.33+47.7%-27.8%$1.96B$723.55M13.621,761Insider TradeRVMDRevolution Medicines4.6632 of 5 stars$44.89-0.3%$63.67+41.8%+69.6%$7.55B$11.58M-12.54443Positive NewsLNTHLantheus4.4014 of 5 stars$94.27+1.3%$130.00+37.9%+21.9%$6.55B$1.50B15.42834Positive NewsLEGNLegend Biotech1.6722 of 5 stars$33.83-3.7%$81.54+141.0%-43.4%$6.18B$520.18M-36.971,800NUVLNuvalent2.3399 of 5 stars$86.65-0.2%$112.60+29.9%+9.7%$6.16BN/A-25.0340Positive NewsBPMCBlueprint Medicines2.9172 of 5 stars$95.39+2.4%$122.11+28.0%+9.7%$6.06B$249.38M-44.17640Insider TradeShort Interest ↑ELANElanco Animal Health4.2802 of 5 stars$12.13+0.2%$16.75+38.1%-10.5%$6.00B$4.45B30.259,300CYTKCytokinetics3.9849 of 5 stars$49.17+1.1%$83.93+70.7%+32.5%$5.80B$3.22M-9.04250TGTXTG Therapeutics3.8084 of 5 stars$34.78+8.6%$40.67+16.9%+81.7%$5.41B$233.66M-320.17290Positive NewsVKTXViking Therapeutics4.2798 of 5 stars$48.07+2.2%$106.75+122.1%+147.1%$5.36BN/A-51.5620BBIOBridgeBio Pharma4.7325 of 5 stars$27.86+1.3%$47.69+71.2%-29.3%$5.27B$217.77M-11.63400Analyst Forecast Related Companies and Tools Related Companies RVMD Competitors LNTH Competitors LEGN Competitors NUVL Competitors BPMC Competitors ELAN Competitors CYTK Competitors TGTX Competitors VKTX Competitors BBIO Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AMPH) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amphastar Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amphastar Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AMPH Stock Alerts